In
Life Technologies Corp. v. Promega Corp., Slip Op. 14-1538
(Feb. 22, 2017), the U.S. Supreme Court held that the supply of a
single component of a multicomponent invention for manufacture
abroad does not give rise to liability under 35 U.S.C. §
271(f)(1). The Court's decision is important for
manufacturers of kit components and those that license and
aggregate those components into a single commercial kit.
The Licensed Technology
Respondent Promega Corp. (Promega) was the exclusive licensee of
U.S. Re. No. 37,984 titled "Process for analyzing length
polymorphisms in DNA regions" and referred to by the Court as
the "Tautz patent." The reissued patent covers kits and
methods, one element of which is the Taq polymerase
enzyme. For the purpose of the litigation, the parties agreed
"that the kit covered by the Tautz patent contains five
components: (1) a mixture of primers that mark the part of the DNA
strand to be copied; (2) nucleotides for forming replicated